Printed One by One, Regulated by None

Additive manufacturing (3D printing) is increasingly used to produce patient-specific medical devices — surgical guides, cranial plates, spinal cages, dental prosthetics — and emerging bioprinting technologies aim to fabricate living tissue constructs. But the FDA's regulatory framework was designed for mass-manufactured devices produced under controlled factory conditions, not for one-off devices fabricated at the point of care in hospital 3D printing labs. It is unclear whether a hospital printing a patient-specific surgical guide is a "manufacturer" subject to FDA oversight, what quality management system requirements apply, and how postmarket surveillance works for one-of-a-kind devices. For bioprinted constructs incorporating living cells, no FDA-approved product exists and no regulatory pathway adequately addresses the unique risks of combining device and biologic properties.

Over 100 U.S. hospitals now operate 3D printing labs producing patient-specific surgical planning tools, guides, and implants. The global medical 3D printing market is projected to exceed $5 billion by 2028. Point-of-care manufacturing offers same-day surgical guides and anatomically matched implants — real clinical benefits — but uncontrolled quality means defective devices may reach patients without the safety checks that centralized manufacturing provides. Bioprinting, while still largely pre-clinical, has the potential to address organ transplant shortages, but regulatory uncertainty is cited as a primary barrier to clinical translation.

The FDA issued guidance on "Technical Considerations for Additive Manufactured Medical Devices" in 2017, but it was written for factory-based additive manufacturing and does not specifically address point-of-care manufacturing. The FDA has suggested that point-of-care devices might be regulated as custom devices (exempt from premarket review under certain conditions) or as manufacturer-specific cleared devices, but neither pathway is clearly defined. ASTM published F3559 in April 2024 — the first standard for bioprinting terminology and considerations for bioinks — but it covers only extrusion bioprinting and focuses on terminology rather than safety validation. A 2025 industry survey found that manufacturers consider FDA additive manufacturing guidance ambiguous and requiring further clarity. Quality control for point-of-care 3D printing currently relies on hospital-specific institutional protocols that vary widely, with no standardized validation methodology.

A regulatory framework that distinguishes between factory-based and point-of-care additive manufacturing — with clear registration, quality management, and validation requirements for hospital-based 3D printing — would resolve the current jurisdictional ambiguity. For bioprinted products, a classification pathway that accounts for the device-biologic combination (currently falling between CDRH and CBER jurisdictions) would unblock clinical translation. Non-destructive testing methods capable of validating patient-specific geometries without destroying the actual device would solve the fundamental quality assurance challenge.

A student team could survey 3D printing labs across multiple hospitals to document current quality management practices, identify common failure modes, and propose a minimum-viable quality standard for point-of-care manufacturing. Alternatively, a team could develop a non-destructive testing protocol for a specific class of 3D-printed device (e.g., surgical guides), comparing printing parameters, material properties, and dimensional accuracy across different printer platforms. A design-focused team could prototype a quality assurance workflow — from digital file to finished device — that a hospital 3D printing lab could adopt.